Clinical Trial Update: TLN-372 in Advanced KRAS Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Treeline Biosciences announced an ongoing Phase 1 trial of TLN-372 for advanced KRAS-mutant solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras-mutant Solid Tumors

Drugs mentioned

• TLN-372

Snippet

Sponsor: Treeline Biosciences, Inc. | Conditions: KRAS Mutant Solid Tumors | Phase 1 | Status: RECRUITING